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Takotsubo cardiomyopathy (TTC) is characterized by reversible left ventricular apical and/or midventricular hypokinesia with
unknown etiology. The clinical presentation is similar to acute myocardial infarction in the absence of significant obstructive
coronary artery disease. Various predisposing factors have been related to TTC, such as acute neurological illnesses, endocrine
diseases, pain, and emotional stress. We present the first description of an association between TTC cardiomyopathy and
panhypopituitarism. This case reinforces the connection between the hormonal and cardiovascular systems. Furthermore, it
supports the importance of a comprehensive and integrated medical history in the approach of a patient with cardiac disease,
towards clinical decision-making.
1. Introduction
Takotsubo cardiomyopathy (TTC) is a novel cardiomyopathy
that has been firstly described by Sato et al. [1] as an important
consideration in the differential diagnosis of acute coronary
syndrome. The presenting features of TTC are similar to
those of myocardial ischemia after acute plaque rupture,
but the characteristic distinctions are regional wall motion
abnormalities that extend beyond a single coronary vascular
bed and the absence of epicardial coronary occlusion. A
preceding emotional or physical stressor is common [2].
The presentation can include life-threatening symptoms and
hemodynamic compromise. Recently a substantial rate of
death and complications after the acute phase of TTC was
shown, with a long-term follow-up revealing a significant rate
of death from any cause (5.6% per patient-year) and a rate of
major adverse cardiac and cerebrovascular events (9.9% per
patient-year) [2].
Marked increased levels of catecholamines and meta-
nephrines are found in the acute phase and they proba-
bly account for a possible acute coronary spasm and/or
focal myocardial dysfunction with contraction band necro-
sis/myocytolysis underlying the clinical condition [3]. Since
the prognosis is much better and a different pharmaco-
logic approach is required, angiotensin-converting–enzyme
inhibitors or angiotensin receptor blockers are preferred [2],
while inotropes should be avoided; the differential diagnosis
is crucial [4]. Little is known about individual susceptibility
to TTC. However increased sympathetic autonomic activity
might be casually related. More rarely it may be related to a
diseased hypothalamic-pituitary-adrenal axis (HPA), proba-
bly requiring chronic increased compensatory hyperactivity
of the sympathetic autonomic system [5].We report a clinical
case supporting that association.
2. Case Presentation
A 74-year-old man presented at the emergency department
with chest pain, palpitations, and progressive dyspnea within
the last 24 hours. He had a past history of high blood
pressure and dyslipidemia and was being treated with lisino-
pril/hydrochlorothiazide and simvastatin; an acquired atri-
oventricular block was managed with DDDR pacing. In the
last year, fatigue, asthenia, adynamia, cold intolerance, loss
of muscular strength, anorexia, decreased libido, and loss of
male hair pattern distribution were also reported, with blood
pressure decreasing whereat lisinopril/hydrochlorothiazide
was interrupted. On physical examination, blood pressure
was 102/84mmHg, heart rate 65 beats perminute, respiratory
rate 28 breaths per minute, and normal oxygen saturation
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Figure 1: (a) Initial electrocardiogram showing an atrioventricular sequential paced rhythm with left bundle branch block morphology
complexes, no ST-segment deviation, deeply inverted T waves on DI, aVL and precordial leads, and a prolonged QTc interval (560ms). (b)
Electrocardiogram 3 months after discharge.
(a) (b)
Figure 2: (a) Transthoracic echocardiography (apical four-chamber view) during the initial admission, demonstrating apical ballooning
(white arrows). (b) Left ventriculography images in diastole and systole, showing typical type of takotsubo cardiomyopathy with apical
ballooning, dyskinesia (white arrows), and left ventricle basal hypercontractility.
(ambient air) and temperature 36.6∘C. He had signs of
heart failure (jugular venous distention, peripheral edema,
and pulmonary congestion) and cardiac auscultation was
remarkable for a protodiastolic gallop.
Electrocardiogram showed an atrioventricular sequential
paced rhythm with left bundle branch block morphology
complexes, no ST-segment deviation, deeply inverted T
waves on DI, aVL and precordial leads, and a prolonged
QTc interval (560ms) (Figure 1(a)). Complete blood count,
serum electrolytes, renal function parameters, and glycaemia
were normal. Troponin I (<0.07 ng/mL) was mildly elevated
(0.79 ng/mL). Echocardiography showed a nondilated left
ventricle with apical dyskinesia and hyperdynamic basal
contraction assuming a systolic ballooning pattern, and a
moderately depressed (37%) ejection fraction (Figure 2(a);
Video 1 in Supplementary Material available online at
http://dx.doi.org/10.1155/2016/9219018).
Acute coronary syndrome and TTC were considered
in the differential diagnosis. Coronarography showing no
significant coronary artery disease and a left ventriculogram
revealing the typical apical ballooning (Figure 2(b); Video
2) favor the former hypothesis. Cardiac magnetic resonance
was not performed given the presence of a noncompatible
pacemaker.
During hospitalization the patient was managed with
diuretics, beta-blocker, and angiotensin-converting enzyme
inhibitor. Laboratory data showed a peak troponin I of
1,38 ng/mL.Pheochromocytoma/paragangliomawas excluded
by urinarymeta- and normetanephrinesmeasurement (High
Performance Liquid Chromatography) and the patient was
referred for endocrine consultation.
A formal pituitary dynamic test was performed after
an overnight fast: growth hormone-releasing hormone
100 𝜇g, corticotropin-releasing hormone 100 𝜇g, thyrotropin-
releasing hormone 200𝜇g, and gonadotropin-releasing hor-
mone 100 𝜇g bolus (intravenous) at time 0; baseline/peak
hormone levels were as follows: growth hormone (<2 ng/mL):
0.15/0.18; prolactin (2–18 ng/mL): 21/35; cortisol (4–23 𝜇g/
dL): 1.5/4.1; follicle-stimulating hormone (1–18U/L): 2.2/2.8;
luteinizing hormone (3–35U/L): 0.3/1.1; other baseline val-
ues were insulin-like growth factor 1 (48–188 ng/mL): 33;
adrenocorticotropin (0–46 pg/mL): 31; triiodothyronine (60–
181 ng/dL): 81; thyroxine (4.5–10.9 𝜇g/dL): 2.2; free thyroxine
(0.89–1.80 ng/dL): 0.42; total testosterone (188–772 ng/dL):
<10. All measurements were obtained with standardized
chemiluminescence immunoassays; age and gender specific
reference values at 8.00–10.00 h am after an overnight fast
are presented within square brackets.Thyroid autoantibodies
were negative.
Brain magnetic resonance imaging revealed a normal
sized and positioned pituitary gland with no morphological
abnormalities and a centered pituitary stalk.
A diagnosis of idiopathic panhypopituitarism was estab-
lished and the patient was prescribed hydrocortisone 20 +
10mg daily (oral), levothyroxine 100𝜇g daily (oral), and
testosterone enanthate 250mg every fortnight (intramuscu-
lar). The usual instructions were given orally and by writing
regarding stressful conditions.
After 3 months of optimized heart failure treatment the
patient showed clinical improvement, normalization of left
ventricular function, and reversibility of T waves changes
and QT prolongation (Figure 1(b)). Interestingly, in this case,
the repolarization changeswere clearly interpretable notwith-
standing the presence of a right ventricular paced rhythm. In
that time, lost weight was recovered and the patient regained
normal physical vigour without other complaints.
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3. Discussion
This case begins with an unusual presentation of TTC.There
was no record for any particular acute emotional or physical
stress; the patient is male while TTC is much more common
in women and the presentation is that of an acute coronary
syndrome with marked left ventricular dysfunction [3, 6].
TTC is an acute, reversible dysfunction of the left ventri-
cle in the absence of significant obstructive coronary disease.
Recently, Templin et al. [2] prospectively showed that the
most common pattern was the apical type (81.7%) followed
by the midventricular (14.6%), the basal (2.2%), and the
focal (1.5%) types. The condition is especially prevalent in
postmenopausal women but the true prevalence of TTC
remains uncertain because of its underrecognition.The long-
term prognosis is generally favorable.The pathophysiology of
TTC is not established but is likely multifactorial, involving
the vascular, endocrine, and central nervous systems. Several
mechanisms have been postulated to link the sympathetic
hyperactivity and myocardial dysfunction including diffuse
coronary artery spasm, coronary microcirculation alter-
ations, and direct catecholamine mediated myocyte injury
[3, 7]. In 70% of the documented cases there is an apparent
trigger leading to catecholamine-induced myocardial injury
[6]. Further investigation is needed to define the connection
between these triggers and their effect on the vulnerable
myocardium.
In the acute phase, TTC is sometimes indistinguishable
from acute myocardial infarction with respect to clinical
symptoms, ECG changes, and cardiac biomarkers such as
troponin and creatine kinase. Fast and accurate diagnosis on
admission remains challenging, and exclusion of significant
obstructive coronary artery disease is mandatory.Thus, there
is a need for sensitive and specific biomarkers for the early
diagnosis of TTC. MicroRNAs are a class of highly con-
served and small noncoding posttranscriptional regulators of
diverse cellular processes that have been recently considered
as biomarkers in cardiovascular disease [8]. Jaguszewski et al.
[9] recently described a signature of circulating microRNAs
for sensitive and specific identification of TTC in the acute
phase.The significant upregulation of stress- and depression-
related microRNAs suggested a role of central and/or periph-
eral nervous system in TTC.
Retrospectively the patient of our case presented com-
plains suggesting pituitary failure—low blood pressure, cold
intolerance, loss of physical vigour andmotivation, decreased
libido, scanty body hair—although this is a rare condition,
and these symptoms are by themselves rather common in
older men [7]. Endocrine evaluation unequivocally revealed
complete anterior pituitary failure, but the reason is not
apparent. Combined pituitary failure by itself is a very
rare condition—estimated prevalence 46/100.000 and esti-
mated annual incidence 4/100.000—and at least in adult/old
patientsmost commonly depends on pituitary tumors [10, 11].
Other less common causes include head trauma [12], for
which the patient had no recollection and besides pituitary
stalk section generally occurs; hemochromatosis and other
metabolic conditions, for which no evidence was found in
this case (iron, transferrin, and ferritin levels were normal
and the pituitary was not enlarged); vascular, that would be
likely in this age group, namely, subarachnoid, hemorrhage
[13]. However, there was no evidence for pituitary apoplexy
at the CT scan. In fact most other conditions leading to
combined pituitary failure, namely, infections, inflammatory,
granulomatous, immune, or neoplastic disorders, generally
present with structural abnormalities in the pituitary gland
that can be shown by MRI [7, 10, 11]. Of course a congenital
or genetic and functional defect is mostly unlikely, given
patient age and clear evidence for previous normal growth
and development, including two fathered children. In short,
unequivocal combined pituitary failure is present but the rea-
son is unclear.This occurs in around 10–20% of the cases, and
an etiology sometimes is apparent only many years later [14].
An acute and transient defect is also unlikely since the patient
had previous evidence of pituitary failure and maintained
that condition for as long as two years of follow-up requiring
substitutive therapy. Also, the possibility of a neuroendocrine
adaptation to an acute/chronic condition may be discarded.
That adaptation, for which the nonthyroidal patient syn-
drome is the best-known pattern, is associated with increased
cortisol levels [15]. By the same token, a drug effect is
unlikely.
Besides someperplexing features, amost interesting point
can be made that progressive multiple pituitary failure may
require an increased sustained sympathetic activity to cope
with daily life physical and emotional challenges, since it is
by itself certainly a stressful condition. Curiously enough,
to our knowledge, other reports of TTC and endocrine
disease always resolve around the theme of pheochromo-
cytoma [16] or failure of the HPA axis [5, 17, 18]; to our
knowledge, this is the first report of the association of
TTC with adult onset multiple pituitary hormonal fail-
ure. Chronic activation of the sympathetic nervous system
may on the other hand favor the development of TTC,
as has been suggested by some reports regarding behav-
ioral medicine [3]. Regarding combined pituitary failure,
increased sympathetic drive may be particularly deleterious,
since androgens may downregulate the stress response and
may present direct vasodilator effects on coronary arter-
ies [19], and low testosterone predicts the development of
atherosclerosis and cardiovascular events [20] while gluco-
corticoids may play a supportive role on myocardial function
[21] and hypothyroidism may impair coronary blood flow
[22].
TTC represents an acute heart failure syndrome that is
associated with a substantial risk for adverse events.The great
variety of triggering factors in this disease needs to be illu-
minated and new investigations are required. Furthermore,
a heightened vigilance in the treatment of these patients is
crucial to improve prognosis.
In a way, the gap is narrowing between “Voodoo death”
[23] as described by Sir Cannon in the 40s and TTC
reported in the 90s. It remains to be seen if this association
of combined pituitary failure and TTC is also reported
by other authors. TTC by itself was also a long present
but unknown condition until Sato first formally described
it.
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